Search Result

Results for "

FcγR

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (1) Btk (3) c-Kit (1) Caspase (1) CD20 (1) CD3 (1) CD73 (1) Complement System (1) Drug Derivative (1) ERK (1) Fc Receptor (FcR) (3) Microtubule/Tubulin (1) PKC (1) Radionuclide-Drug Conjugates (RDCs) (1) TNF Receptor (3) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (13) Infection (1) Inflammation/Immunology (7) Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99742

Mitazalimab 1 Publications Verification ADC-1013; JNJ-64457107; Vanalimab	TNF Receptor	Cancer
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment .

HY-P9954

Catumaxomab	CD3	Cancer
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .

HY-P99181

Mupadolimab CPI-006	CD73	Infection Inflammation/Immunology Cancer
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73 ^POS B cells .

HY-P99529

Valziflocept BAX1810; TAK-752; SM101	Fc Receptor (FcR)	Inflammation/Immunology
Valziflocept (BAX1810) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind to and neutralize pathogenic IgG, thereby acting as a "decoy" or "scavenger" receptor that reduces the severity of autoimmune diseases. Valziflocept is used in research on autoimmune diseases such as systemic lupus erythematosus (SLE) .

HY-P991192

BI-1808	TNF Receptor	Cancer
BI-1808 is a human IgG1 monoclonal antibody that targets TNFR2by blocking interaction of TNFR2 with ligand TNF-α, confers FcγR-dependent depletion of Treg and mediates expansion of intratumoral CD8 ⁺ T cells .

HY-177578

NN3201	Antibody-Drug Conjugates (ADCs) c-Kit Apoptosis Microtubule/Tubulin ERK Akt Caspase	Cancer
NN3201 is a c-Kit-targeting antibody-drug conjugate (ADC) with high affinity (K_D = 0.19 pM). NN3201 is composed of 4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE (HY-178219) and an anti-c-Kit human monoclonal antibody NN2101 (HY-P991293). NN3201 rapidly internalizes and inhibits stem cell factor (SCF)-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits no Fc-mediated effector functions antibody-dependent cell-mediated cytotoxicity (ADCC)/complement-dependent cytotoxicity (CDC) due to reduced FcγR binding. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models. NN3201 can be used in small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) and acute myeloid leukemia (AML) research ^[1][2].

HY-P991193

NGM-438	TNF Receptor	Cancer
NGM-438 is a humanized monoclonal antibody antagonist of LAIR1, with a K_a of 0.26 nM for human LAIR1 and 4.28 nM for cynomolgus monkey LAIR1. NGM-438 blocks the binding of LAIR1 to its Collagen ligand and antagonizes the Collagen-induced LAIR1 signaling pathway. NGM-438 reverses FcγR signaling inhibition in myeloid cells, induces dendritic cells to secrete TNFα, promotes T cell proliferation, and triggers myeloid inflammation and allogeneic T cell responses. NGM-438 sensitizes refractory mouse lung cancer to PD-1 blockade, increases the content of intratumoral CD8 ⁺ T cells and the expression of inflammatory genes. NGM-438 is applicable to research related to solid tumors, refractory solid tumors and non-small cell lung cancer .

HY-147584

BTK-IN-14	Btk	Inflammation/Immunology Cancer
BTK-IN-14 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-14 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022057894A1, compound 1) .

HY-P991514

MIL62	CD20	Cancer
MIL62 is an anti-CD20 monoclonal antibody. MIL62 shows enhanced affinity for the FcγRⅢa receptors and direct B-cell killing effects. MIL62 has antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MIL62 can be used for the study of non-Hodgkin lymphoma (NHL) .

HY-P10085

PKC-ε translocation inhibitor peptide	PKC	Inflammation/Immunology
PKC-ε translocation inhibitor peptide is a PKC-ε translocation inhibitor. PKC-ε translocation inhibitor peptide can regulate the rate of FcγR-mediated internalization of opsonized beads, has no effect of FcαR trafficking .

HY-P991387

AGEN1307 AGEN1327	Transmembrane Glycoprotein	Cancer
AGEN1307 is a human monoclonal antibody (mAb) targeting TIGIT. AGEN1307 has an active FcγR binding region and enhances antibody-dependent cellular cytotoxicity (ADCC). AGEN1307 can be used in cancer research .

HY-147581

BTK-IN-11	Btk	Inflammation/Immunology Cancer
BTK-IN-11 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-11 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022063101A1, compound Z2) .

HY-P991922

AKIR001	Fc Receptor (FcR) Complement System Radionuclide-Drug Conjugates (RDCs)	Cancer
AKIR001 is a high-affinity human IgG1 antibody targeting CD44v6. AKIR001 carries LALA-silencing mutations in its FcγR-binding domain to reduce FcγR and C1q interactions, minimizing tissue interactions and limiting CDC and ADCC risks. [ ¹⁷⁷Lu] radiolabeled AKIR001, namely [ ¹⁷⁷Lu]Lu-AKIR001, has anticancer activity against epidermoid carcinoma .

HY-182943

BTK-IN-49	Btk Fc Receptor (FcR)	Neurological Disease Inflammation/Immunology
BTK-IN-49 is a selective, orally active and brain-penetrant BTK inhibitor with an IC₅₀ of 0.14 nM. BTK-IN-49 binds to BTK and blocks B-cell receptor and Fcγ receptor signaling. BTK-IN-49 inhibits the proliferation of CNS-compartmentalized B-cells and FcγR-induced microglial proliferation in a BTK-dependent manner. BTK-IN-49 can be used for the study of multiple sclerosis .

HY-P9S0124

Anti-CD33 Antibody (OR000283) ORM-6151 Antibody; BMS-986497 Antibody		Cancer
Anti-CD33 Antibody (OR000283) (ORM-6151 Antibody; BMS-986497 Antibody) is an antibody targeting CD33. It is generated by grafting the FAb (H&L) sequence of Gemtuzumab (HY-P99971) onto an IgG1 Fc carrying the N297A mutation, which inhibits Fc-γR binding. Anti-CD33 Antibody (OR000283) can be used to construct degrader-antibody conjugates (DACs), such as ORM-6151 (HY-171792) .

HY-P992381

IBI352g4a	Drug Derivative	Cancer
IBI352g4a is a humanized IgG1 monoclonal antibody targeting PVRIG (K_d = 0.53 nM) and acts as a PVRIG/PVRL2 inhibitor. The anti-tumor effect of IBI352g4a depends on the binding of its Fc region to FcγR. IBI352g4a binds to the extracellular domains of human and cynomolgus monkey PVRIG, and blocks the PVRIG-PVRL2 interaction. IBI352g4a induces NK cell activation, promotes their degranulation and tumor killing. IBI352g4a can be used in the research of gastric cancer .

Cat. No.	Product Name	Target	Research Area

HY-P10085

PKC-ε translocation inhibitor peptide	PKC	Inflammation/Immunology
PKC-ε translocation inhibitor peptide is a PKC-ε translocation inhibitor. PKC-ε translocation inhibitor peptide can regulate the rate of FcγR-mediated internalization of opsonized beads, has no effect of FcαR trafficking .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99742

Mitazalimab 1 Publications Verification ADC-1013; JNJ-64457107; Vanalimab	TNF Receptor	Cancer
Mitazalimab (ADC-1013; JNJ-64457107) is FcγR-dependent CD40 agonist with tumor-directed activity. Mitazalimab activates antigen-presenting cells, e.g. dendritic cells (DC), to initiate tumor-reactive T cells. Therefore, Mitazalimab induces tumor-specific T cells to infiltrate and kill tumors. Mitazalimab remodels the tumor-infiltrating myeloid microenvironment .

HY-P9954

Catumaxomab	CD3	Cancer
Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers .

HY-P99181

Mupadolimab CPI-006	CD73	Infection Inflammation/Immunology Cancer
Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73 ^POS B cells .

HY-P99529

Valziflocept BAX1810; TAK-752; SM101	Fc Receptor (FcR)	Inflammation/Immunology
Valziflocept (BAX1810) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind to and neutralize pathogenic IgG, thereby acting as a "decoy" or "scavenger" receptor that reduces the severity of autoimmune diseases. Valziflocept is used in research on autoimmune diseases such as systemic lupus erythematosus (SLE) .

HY-P991192

BI-1808	TNF Receptor	Cancer
BI-1808 is a human IgG1 monoclonal antibody that targets TNFR2by blocking interaction of TNFR2 with ligand TNF-α, confers FcγR-dependent depletion of Treg and mediates expansion of intratumoral CD8 ⁺ T cells .

HY-P99983

Mouse IgG1 (D265A) kappa, Isotype Control	Inhibitory Antibodies	Inflammation/Immunology
Mouse IgG1 (D265A) kappa, Isotype Control is a mouse IgG1(D265A)κ isotype control with a D265A mutation and inactivity against mouse Fc gamma receptors (Fc*γR1, FcγR2, FcγR3, FcγR4*) .

HY-P991193

NGM-438	TNF Receptor	Cancer
NGM-438 is a humanized monoclonal antibody antagonist of LAIR1, with a K_a of 0.26 nM for human LAIR1 and 4.28 nM for cynomolgus monkey LAIR1. NGM-438 blocks the binding of LAIR1 to its Collagen ligand and antagonizes the Collagen-induced LAIR1 signaling pathway. NGM-438 reverses FcγR signaling inhibition in myeloid cells, induces dendritic cells to secrete TNFα, promotes T cell proliferation, and triggers myeloid inflammation and allogeneic T cell responses. NGM-438 sensitizes refractory mouse lung cancer to PD-1 blockade, increases the content of intratumoral CD8 ⁺ T cells and the expression of inflammatory genes. NGM-438 is applicable to research related to solid tumors, refractory solid tumors and non-small cell lung cancer .

HY-P991514

MIL62	CD20	Cancer
MIL62 is an anti-CD20 monoclonal antibody. MIL62 shows enhanced affinity for the FcγRⅢa receptors and direct B-cell killing effects. MIL62 has antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MIL62 can be used for the study of non-Hodgkin lymphoma (NHL) .

HY-P991387

AGEN1307 AGEN1327	Transmembrane Glycoprotein	Cancer
AGEN1307 is a human monoclonal antibody (mAb) targeting TIGIT. AGEN1307 has an active FcγR binding region and enhances antibody-dependent cellular cytotoxicity (ADCC). AGEN1307 can be used in cancer research .

HY-P991922

AKIR001	Fc Receptor (FcR) Complement System Radionuclide-Drug Conjugates (RDCs)	Cancer
AKIR001 is a high-affinity human IgG1 antibody targeting CD44v6. AKIR001 carries LALA-silencing mutations in its FcγR-binding domain to reduce FcγR and C1q interactions, minimizing tissue interactions and limiting CDC and ADCC risks. [ ¹⁷⁷Lu] radiolabeled AKIR001, namely [ ¹⁷⁷Lu]Lu-AKIR001, has anticancer activity against epidermoid carcinoma .

HY-P9S0124

Anti-CD33 Antibody (OR000283) ORM-6151 Antibody; BMS-986497 Antibody		Cancer
Anti-CD33 Antibody (OR000283) (ORM-6151 Antibody; BMS-986497 Antibody) is an antibody targeting CD33. It is generated by grafting the FAb (H&L) sequence of Gemtuzumab (HY-P99971) onto an IgG1 Fc carrying the N297A mutation, which inhibits Fc-γR binding. Anti-CD33 Antibody (OR000283) can be used to construct degrader-antibody conjugates (DACs), such as ORM-6151 (HY-171792) .

HY-P992381

IBI352g4a	Drug Derivative	Cancer
IBI352g4a is a humanized IgG1 monoclonal antibody targeting PVRIG (K_d = 0.53 nM) and acts as a PVRIG/PVRL2 inhibitor. The anti-tumor effect of IBI352g4a depends on the binding of its Fc region to FcγR. IBI352g4a binds to the extracellular domains of human and cynomolgus monkey PVRIG, and blocks the PVRIG-PVRL2 interaction. IBI352g4a induces NK cell activation, promotes their degranulation and tumor killing. IBI352g4a can be used in the research of gastric cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.